---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106910"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:41:05.809457+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Korro Bio Q2 2025 net loss $25.8M; cash $119.6M; KRRO-110 interim data on track H2 2025

## Summary
- Cash, cash equivalents and marketable securities of $119.6M as of June 30, 2025, expected to fund operations into 2027.
- Net loss $25.8M for Q2 2025 vs $21.8M in Q2 2024; R&D expenses $21.0M (up from $17.1M).
- Collaboration revenue of $1.5M from Novo Nordisk partnership; zero collaboration revenue in prior year quarter.
- Phase 1/2a REWRITE trial of KRRO-110 for AATD: over 80% of planned healthy volunteers dosed; interim SAD readout expected H2 2025.
- KRRO-110 received EMA Orphan Drug Designation for AATD; rare metabolic disorder development candidate to be announced by end of 2025.

## SEC filing metadata
- accession: 0000950170-25-106910
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017025106910/0000950170-25-106910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017025106910/krro-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106910
- JSON: https://secwatch.observer/filing/0000950170-25-106910.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106910.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.